Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0SLVXU
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Belantamab-Compound (XLI)
|
|||||
| Synonyms |
Belantamab Compound (XLI)
Click to Show/Hide
|
|||||
| Organization |
Orum Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Multiple myeloma [ICD11:2A83]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Belantamab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Belantamab-Compound (XLI) linker
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.